Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBOV-548
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**EBOV-548** is a human monoclonal antibody developed for the treatment of Ebola virus disease (EVD). It exhibits broad reactivity against glycoproteins (GP) from multiple ebolavirus species, including Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV), and demonstrates neutralizing activity specifically against EBOV and BDBV. The antibody recognizes intact but not cleaved GP, contributing to its antiviral mechanism by preventing viral entry. It has been studied in combination cocktails, such as with EBOV-520, where it shows synergistic neutralization and therapeutic protection in EBOV-challenged rhesus macaques, highlighting its potential as part of pan-ebolavirus immunotherapies.[1][5][8]
- Other names
- rEBOV-548rEBOV548rEBOV 548
02
Targets
GP glycan cap (Ebolavirus glycoprotein glycan cap)
Beyond the preview
Go deeper on EBOV-548.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBOV-548.